• Sign In
  • Sign Out
  • My Account
Subscribe
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
  • Special reports
Clarivate
  • Data Snapshots
  • BioWorld
  • BioWorld MedTech
  • Infographics: Dynamic digital data analysis
  • Special reports
  • Infographics: Dynamic digital data analysis
  • Trump administration impacts
  • Biopharma M&A scorecard
  • BioWorld 2024 review
  • BioWorld MedTech 2024 review
  • BioWorld Science 2024 review
  • Women's health
  • China's GLP-1 landscape
  • PFA re-energizes afib market
  • China CAR T
  • Alzheimer's disease
  • Israel
  • Rise of obesity
  • Radiopharmaceuticals
  • Biosimilars
  • Aging
  • IVDs on the rise
  • Coronavirus
  • Artificial intelligence

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Israel
    • Rise of obesity
    • Radiopharmaceuticals
    • Biosimilars
    • Aging
    • IVDs on the rise
    • Coronavirus
    • Artificial intelligence

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
Home » Newsletters » BioWorld

BioWorld

Nov. 4, 2016

View Archived Issues

Biopharma, med tech have a lot riding on congressional elections

While headlines, social media and news reports are buzzing with the latest poll numbers and the he said/she saids of the U.S. presidential campaign, what happens in Congress could have a bigger impact on the biopharma and med-tech universe. Read More

Intercept, Alimera, Amarin, Amag and more all lose ground on earnings

Shares of Intercept Pharmaceuticals Inc. (NASDAQ:ICPT) fell nearly 16.5 percent to close at $98.20 on Thursday as the company reported third-quarter revenue of $5.2 million, primarily attributed to its biliary cholangitis (PBC) therapy, Ocaliva (obeticholic acid), sales of which narrowly missed analyst expectations. Net losses at the New York-based company totaled $88.8 million vs. about $51 million in the third quarter of 2015, a period before Intercept made the jump to being a commercial company. Read More

'Strips' of heart tissue improve cardiac function

Researchers have been able to significantly improve the heart function of guinea pigs after an experimentally induced heart attack by transplanting the animals with sheets of induced pluripotent stem cell (iPSC)-derived human heart cells. Read More

In the clinic

Epizyme Inc., of Cambridge, Mass., provided an update on new trials with tazemetostat, its EZH2 inhibitor. Combination studies with Tecentriq (atezolizumab) and R-CHOP therapy have started, and the phase Ib combination study with anti-PD-L1 antibody Tecentriq in patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) has initiated in collaboration with Roche Holding AG, of Basel, Switzerland. Read More

Financings

Zucara Therapeutics Inc., of Vancouver, British Columbia, said it received a C$525,000 (US$391,866) investment from Canadian partners: Accel-Rx Health Sciences Accelerator, The Centre for Drug Research and Development and MaRS Innovation. Zucara is a preclinical-stage company working on a long-term approach to prevent hypoglycemia in patients with diabetes. The company said it plans to seek series A funding next year to take it through clinical studies, set to start in 2018. Read More

Other news to note

Acasti Pharma Inc., of Laval, Quebec, said the firm applied and received authorization to change its stock ticker to ACST on the TSX Venture Exchange, effective Nov. 8. The change was made due to the recent introduction of four-letter root symbols on the TXSV. Read More

Australian biotechs lap up big pharma attention over recent deal activity

MELBOURNE, Australia – Some big deals in the biopharma space in Australia over the last year have gotten the attention of big pharma, and the sector is keyed up over the courtship possibilities. Read More

Panel: Shift focus to manufacturing as cell therapies near market

LONDON – A number of cell-based cancer immunotherapies are months from being filed with regulators, but, in the rush to prove safety and efficacy, manufacturing issues have been overlooked. Read More

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for June 10, 2025.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for June 10, 2025.
  • News in brief

    BioWorld Asia
    BioWorld Asia briefs for June 10, 2025
  • Red blood cells in an artery with cholesterol

    In two phase IIIs, Merck’s PCSK9 inhibitor cuts cholesterol

    BioWorld
    In two phase III studies, Merck & Co. Inc.’s oral, once monthly proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor produced statistically significant...
  • Cancer cell in the cross-hairs

    Pan-cancer proteome atlas reveals new biomarkers and targets

    BioWorld Science
    An international group of scientists has completed the first draft of The Pan-Cancer Proteome Atlas (TPCPA). The project is based on mass spectrometry of 22...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2025. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Israel
    • Rise of obesity
    • Radiopharmaceuticals
    • Biosimilars
    • Aging
    • IVDs on the rise
    • Coronavirus
    • Artificial intelligence

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe